InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
2
T+90 hit rate
100%
T+90 mean return
+21.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Aryeh Jason, Director. Insider active across 3 companies, notably Ligand Pharmaceuticals INC. Cumulatively, 17 reports have been recorded. Split: 0 buy · 2 sells. History available since 4 June 2021. The latest transaction was disclosed on 5 June 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations17 total
836 shares0Common StockSEC:0002001011-26-000103:0
500 sharesCommon StockSEC:0002001011-26-000103:1
4,500 sharesCommon StockSEC:0002001011-26-000103:2
25,907 sharesCommon StockSEC:0001376960-26-000002:0
1,209 shares0Common StockSEC:0002001011-25-000045:0
11,700 shares@ US$4.30100.0% of flowCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-24-132582:0
24,554 sharesCommon StockSEC:0001628280-24-038090:0
5,376 shares0Common Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-24-074012:0
1,252 shares0Common StockSEC:0002001011-24-000055:0
2,406 shares@ US$52.3052.9% of flowCommon StockSEC:0002001011-24-000050:0
2,893 shares@ US$39.3547.1% of flowCommon StockSEC:0002001011-24-000032:0
1,142 shares0Common StockSEC:0000886163-23-000040:0
11,246 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001213900-23-037023:0
51,738 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001213900-23-006188:0
1,004 shares0Common StockSEC:0000886163-22-000085:0
630 shares0Common StockSEC:0000886163-21-000094:0
630 shares0Common StockSEC:0000886163-21-000094
17 of 17 declarations
About Aryeh Jason
Jason Aryeh is a Board Member at Ligand Pharmaceuticals Inc. In this role, he contributes to the governance of the company and to strategic decision-making. His experience in the biopharmaceutical sector is valuable for guiding growth initiatives.
